Axa
HBIO icon

Axa’s Harvard Bioscience HBIO Stock Holding History

Axa’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,367
Closed -$59K – 1317
2019
Q1 		$59K Hold
1,367
– – ﹤0.01% 1303
2018
Q4 		$43K Buy
+1,367
New +$53.9K ﹤0.01% 1287
2018
Q2 		– Sell
-9,815
Closed -$491K – 1377
2018
Q1 		$491K Sell
9,815
-6,935
-41% -$311K ﹤0.01% 1164
2017
Q4 		$553K Buy
16,750
+2,400
+17% +$81K ﹤0.01% 1137
2017
Q3 		$538K Sell
14,350
-3,980
-22% -$118K ﹤0.01% 1092
2017
Q2 		$467K Hold
18,330
– – ﹤0.01% 1067
2017
Q1 		$477K Hold
18,330
– – ﹤0.01% 1087
2016
Q4 		$559K Hold
18,330
– – ﹤0.01% 1030
2016
Q3 		$499K Buy
18,330
+1,130
+7% +$31.4K ﹤0.01% 1025
2016
Q2 		$492K Hold
17,200
– – ﹤0.01% 1012
2016
Q1 		$519K Sell
17,200
-620
-3% -$17.6K ﹤0.01% 987
2015
Q4 		$618K Buy
17,820
+1,510
+9% +$51.6K ﹤0.01% 1000
2015
Q3 		$617K Buy
16,310
+3,774
+30% +$176K ﹤0.01% 1009
2015
Q2 		$715K Buy
12,536
+1,359
+12% +$77.3K ﹤0.01% 1014
2015
Q1 		$650K Sell
11,177
-550
-5% -$29.5K ﹤0.01% 1036
2014
Q4 		$665K Buy
11,727
+887
+8% +$42.3K ﹤0.01% 1052
2014
Q3 		$444K Buy
10,840
+530
+5% +$24.4K ﹤0.01% 1091
2014
Q2 		$469K Hold
10,310
– – ﹤0.01% 1092
2014
Q1 		$489K Buy
10,310
+20
+0.2% +$910 ﹤0.01% 1072
2013
Q4 		$484K Sell
10,290
-3,720
-27% -$162K ﹤0.01% 1073
2013
Q3 		$559K Buy
14,010
+2,693
+24% +$106K ﹤0.01% 977
2013
Q2 		$406K Buy
+11,317
New +$433K ﹤0.01% 1010

Other funds holding HBIO

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ECM
Engine Capital Management New York $828M AUM 6.49% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DGHMC
Dalton, Greiner, Hartman, Maher & Co New York $126M AUM 92.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Axa's HBIO Position: Q2 2019 in Review

Axa sold out of Harvard Bioscience (HBIO) in Q2 2019, closing a stake of 1,367 shares — an estimated $59K sold.

Axa first reported a position in HBIO in Q2 2013 and held it in 22 quarters. The position peaked at $715K in Q2 2015. 78 funds tracked by Wall St. Rank hold HBIO as of Q2 2019.

  • Axa reported no remaining Harvard Bioscience position as of Q2 2019 after selling out during the quarter.
  • Axa sold 1,367 Harvard Bioscience shares in Q2 2019, an estimated $59K.
  • Axa first reported a position in Harvard Bioscience in Q2 2013 and held it in 22 quarters.
  • Axa's Harvard Bioscience position peaked at $715K in Q2 2015.
  • 78 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2019.

Based on Axa's 13F filing for Q2 2019, filed 13 Aug 2019.